8-K: Coya Therapeutics Stockholders Re-Elect Directors and Ratify Auditor at Annual Meeting

Coya Therapeutics, Inc. announced the successful election of three Class III directors and the ratification of Weaver and Tidwell, L.L.P. as its independent registered public accounting firm at its Annual Meeting of Stockholders held on June 26, 2025.

Summary

• Coya Therapeutics, Inc. held its Annual Meeting of Stockholders on June 26, 2025.
• Stockholders voted on two key matters: the election of three Class III directors and the ratification of the company's independent registered public accounting firm.
• Howard Berman, Ph.D., Arun Swaminathan, Ph.D., and Ann Lee, Ph.D., were successfully elected as Class III directors for a three-year term.
• The appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by a significant majority of votes (10,355,085 For vs. 68,851 Against).

Sentiment

Score: 7

Explanation: The document reports routine and successful corporate governance actions, indicating stability and adherence to standard procedures. There are no negative surprises or significant positive catalysts, hence a neutral-to-positive score.

Positives

• All three nominated Class III directors, Howard Berman, Ph.D., Arun Swaminathan, Ph.D., and Ann Lee, Ph.D., were successfully elected, ensuring continuity in board leadership.
• The appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm was overwhelmingly ratified by stockholders, indicating strong support for the company's financial oversight.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding future financial performance or strategic initiatives, focusing solely on the outcomes of the Annual Meeting.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Dated: June 26, 2025 By: /s/ Arun Swaminathan Ph.D. Arun Swaminathan Chief Executive Officer"

Industry Context

This 8-K filing is a routine disclosure for publicly traded companies, particularly in the biotechnology sector, following their annual stockholder meetings. It reflects standard corporate governance practices, ensuring accountability and transparency regarding board composition and financial auditing. The successful election of directors and ratification of auditors are typical outcomes for well-governed companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The successful election of directors and ratification of the auditor reflect the exercise of shareholder voting rights and the maintenance of corporate governance standards.
• Management: The re-election of key directors, including the CEO, provides stability and continuity for the executive team.

Next Steps

• The elected Class III directors will hold office for a term of three years, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms.
• Weaver and Tidwell, L.L.P. will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Coya Therapeutics, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K, Biotechnology, Pharmaceuticals